Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT01292135 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT01292135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01292135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2011
Completion date
May 31, 2013
Enrollment
33 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, small lymphocytic lymphoma